We could not find any results for:
Make sure your spelling is correct or try broadening your search.
MONTREAL, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and...
No dose-limiting toxicities reported in two different weekly doses in heavily pre-treated patients Preliminary evidence of dose response includes significant tumor shrinkage and one patient with...
Addition of investigational RNA-targeted medicines build upon Theratechnologies’ foundational HIV portfolio Submissions to Health Canada planned for 2025 MONTREAL, Dec. 04, 2024 (GLOBE...
MONTREAL, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and...
New financing replaces existing credit facility to optimize Company’s capital structureFavorable interest rates and amortization schedules to free up approximately $19 million in cash in 2025 to...
Resubmission addresses questions raised in January 2024 Complete Response Letter F8 formulation intended to replace EGRIFTA SV® with simplified dosing for the treatment of excess abdominal fat in...
MONTREAL, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on development and...
MONTREAL, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on development and...
Q3 revenue of $22.6 million represents +8% growth year-over-yearPositive net income of $3.1 million or 6 cents per share, and Adjusted EBITDA1 of $7.2 million Fiscal 2024 guidance revised to...
MONTREAL, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on development and...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.09 | 4.59183673469 | 1.96 | 2.28 | 1.96 | 70602 | 2.05865301 | CS |
4 | 0.31 | 17.816091954 | 1.74 | 2.28 | 1.6 | 43203 | 1.92024907 | CS |
12 | 0.4 | 24.2424242424 | 1.65 | 2.28 | 1.6 | 44380 | 1.78320626 | CS |
26 | 0.38 | 22.754491018 | 1.67 | 2.28 | 1.59 | 32486 | 1.81350688 | CS |
52 | -0.04 | -1.91387559809 | 2.09 | 3.43 | 1.59 | 31337 | 1.99435886 | CS |
156 | -14.91 | -87.9127358491 | 16.96 | 17.2 | 1.22 | 35838 | 4.62159166 | CS |
260 | -13.95 | -87.1875 | 16 | 22.4 | 1.22 | 66715 | 10.85286566 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions